IDEAYA Biosciences, Inc. Logo

IDEAYA Biosciences, Inc.

Clinical-stage firm developing precision cancer therapies via synthetic lethality.

IDYA | US

Overview

Corporate Details

ISIN(s):
US45166A1025
LEI:
Country:
United States of America
Address:
5000 SHORELINE CT, SUITE 300, 94080 SOUTH SAN FRANCISCO
Sector:
Mining and quarrying
Industry:
Mining of non-ferrous metal ores

Description

IDEAYA Biosciences, Inc. is a clinical-stage precision medicine oncology company focused on the discovery and development of targeted therapeutics for cancer patients. The company specializes in an approach called synthetic lethality, an emerging class of precision medicine that targets cancer cells by exploiting their specific genetic vulnerabilities. IDEAYA utilizes molecular diagnostics to identify and select patient populations for its potential first-in-class or best-in-class therapies. Its integrated capabilities cover the full development spectrum, from target and biomarker discovery to clinical trials, employing small molecule and protein degrader therapeutic platforms to address unmet needs in oncology.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all IDEAYA Biosciences, Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for IDEAYA Biosciences, Inc.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for IDEAYA Biosciences, Inc. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

OSE Immunotherapeutics Logo
Develops first-in-class immune therapies for oncology and inflammation, partnering for late-stage.
France
OSE
Oxurion NV Logo
Acquires European pharmaceutical subcontractors to build an integrated healthcare services group.
Belgium
OXUR
PA Co., Ltd Logo
Offers HR solutions like recruitment media, staffing, and childcare to revitalize local communities.
Japan
4766
Passage BIO, Inc. Logo
Developing genetic medicines for severe CNS and neurodegenerative disorders.
United States of America
PASG
PCI Biotech Holding Logo
Biopharma firm evaluating its future after discontinuing its core technology development.
Norway
PCIB
PC İLETİŞİM VE MEDYA HİZMETLERİ SANAYİ TİCARET A.Ş. Logo
Integrated media group providing data-driven advertising and media solutions for global brands.
Türkiye
PCILT
PDS Biotechnology Corp Logo
Developing T-cell activating immunotherapies for cancer and infectious diseases.
United States of America
PDSB
Peers Co.,Ltd. Logo
Accelerating tech adoption with consulting, HR services, and proprietary IT/AI solutions.
Japan
7066
PepGen Inc. Logo
Biotech using an EDO platform to treat genetic neuromuscular & neurological diseases.
United States of America
PEPG
PeptiDream Inc. Logo
Discovers peptide therapeutics via a proprietary platform and markets radiopharmaceuticals.
Japan
4587

Talk to a Data Expert

Have a question? We'll get back to you promptly.